CSL delays spin-off, cuts profit outlook as US vaccination rates slide
Update: 2025-10-28
Description
Biotech giant CSL's shares plummet in a dramatic downturn! A profit forecast cut and a delayed vaccine division spinoff send investors reeling. Is U.S. Health Secretary Robert F. Kennedy Jr.'s anti-vaccine stance to blame for the collapse in flu shot rates? Shareholders revolt over executive pay as uncertainty clouds CSL's future.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
